Sodelglitazar

Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.

Safety

Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.

See also

• Elafibranor
• GW0742
• GW501516
• MBX-8025
• Peroxisome proliferator-activated receptor

References